Format

Send to

Choose Destination
Clin Pharmacol Ther. 2015 Jun;97(6):597-606. doi: 10.1002/cpt.117. Epub 2015 Apr 17.

Cannabinoids in late-onset Alzheimer's disease.

Author information

1
Department of Psychogeriatric Medicine, Vincent van Gogh Institute, Venray, The Netherlands.
2
Department of Geriatric Medicine, Radboud Alzheimer Centre, and Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
3
Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.
4
Donders Institute for Brain Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.

Abstract

Given the lack of effective treatments for late-onset Alzheimer's disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing interest in the medicinal uses of cannabinoids, the bioactive components of the cannabis plant, including the treatment of LOAD and other physical conditions that are common in older people. Several in vitro and in vivo studies have demonstrated that cannabinoids can reduce oxidative stress, neuroinflammation, and the formation of amyloid plaques and neurofibrillary tangles, the key hallmarks of LOAD. In addition, in population-based studies, cannabinoids reduced dementia-related symptoms (e.g., behavioral disturbances). The current article provides an overview of the potential of cannabinoids in the treatment of LOAD and related neuropsychiatric symptoms in older people. We also discuss the efficacy, safety, and pharmacokinetics of cannabinoid-based drugs in older people with dementia.

PMID:
25788394
DOI:
10.1002/cpt.117
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center